Recombinant human thrombopoietin is an injectable, mainly administered by subcutaneous injection, and its dosage varies for different diseases. Recombinant human thrombopoietin is mainly used for thrombocytopenia after chemotherapy for solid tumors and idiopathic thrombocytopenic purpura when glucocorticoid therapy is ineffective. It is mainly administered by subcutaneous injection, and the recommended dose is 300 U per kilogram of body weight, administered once a day for 14 consecutive days, and should be discontinued if the absolute value of platelet count is elevated ≥50×10^9/L during administration. Adverse reactions to this product are rare, occasionally muscle pain, fever, dizziness, etc., most of which can be recovered by themselves. It is contraindicated for those who are allergic to this product, those with severe cardiovascular and cerebrovascular diseases, those with hypercoagulable state of blood, and those with severe infections. This product should be used with the help of a physician, if discomfort occurs after administration, please inform the physician.